Targeted therapies have unique toxicity profiles. Common adverse events include rash,
diarrhea, hypertension, hypothyroidism, proteinuria, depigmentation, and hepatotoxicity …

Gastric cancer is one of the most frequent malignancies worldwide. Despite improvements in
diagnosis and therapy, the overall prognosis remains poor. In the last decade, several anti …

Despite improvements in the early diagnosis, prognosis and therapeutic strategies for
gastric cancer (GC), human GC remains one of the most frequently diagnosed malignant …

Background With the wide application of targeted drug therapies, the relevance of
prognostic and predictive markers in patient selection has become increasingly important …

Colorectal cancer has been ranked the third and second most prevalent of all cancers in
men and women, respectively, and it represents the fourth most common cause of cancer …

Background To report the nonrandomized first-in-human phase I trial of PRS-050, a novel,
rationally engineered Anticalin based on human tear lipocalin that targets and antagonizes …

Abstract Purpose The phase III VELOUR trial demonstrated efficacy with combined FOLFIRI‐
aflibercept in patients with metastatic colorectal cancer previously treated with oxaliplatin …

In human patients, drugs that block tumor vessel growth are widely used to treat a variety of
cancer types. Many rigorous phase 3 clinical trials have demonstrated significant survival …

Background Rapid progress over the last decade has added numerous agents targeting
specific cellular signaling pathways to the treatment armamentarium for advanced cancer …

Background Studies suggest a relationship between hypertension and outcome in
bevacizumab-treated patients with metastatic colorectal cancer (mCRC). We performed a …